Copenhagen
,
Denmark
10 - 13 May 2025
Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE), 2025
Presentation schedule and materials
Sunday, 11 May 2025
14:15
- 14:45
CEST
RC6.4 / RC6.4a
ORAL PRESENTATION
Weekly somapacitan is effective and well-tolerated in children born small for gestational age: randomized phase 3 trial
Agnès Linglart1; Volker Böttcher2; Michael Højby3; Carlos Alberto Longui4; Joshua Smith5; Masanobu Kawai6
MATERIALS AVAILABLE
14:15
- 14:45
CEST
RC6.3 / RC6.3a
ORAL PRESENTATION
Weekly somapacitan is effective and well-tolerated in children with idiopathic short stature: randomized phase 3 trial
Jennifer Abuzzahab1; Andrew Dauber2; Michael Højby3; Haruo Mizuno4; Philip Murray5, 6; Moshe Phillip7, 8; Tadej Battelino9
MATERIALS AVAILABLE
16:55
- 17:55
CEST
P633
POSTER
MySoConnect® for Sogroya®: long-acting growth hormone for patients with growth-related disorders and their caregivers
Primož Kotnik1; Barbara Murn Berkopec1; Tadej Battelino1; Sandhya Gopalakrishnan2; Sönke Johannsen3; Liam Mc Morrow4; Klemen Dovč1
MATERIALS AVAILABLE
16:55
- 17:55
CEST
P635
POSTER
Evaluation of features for a digital application for growth hormone therapy using perceptions gathered from patients, caregivers and healthcare professionals
Christa Flück1; Kees Noordam2; Claudia Katschnig3; Sandhya Gopalakrishnan4; Sönke Johannsen5; Melanie Hess6
MATERIALS AVAILABLE
16:55
- 17:55
CEST
P634
POSTER
Efficacy and safety of somapacitan versus daily growth hormone at 52 weeks in patients with growth hormone deficiency: pooled analysis of the randomised REAL 3, REAL 4 and REAL 6 clinical trials
Lars Sävendahl1; Aristides Maniatis2; Martin Wabitsch3; Alberto Pietropoli4; Nicky Kelepouris5; Michael Højby6; Junfen Fu7; Jun Mori8; Bradley S. Miller9
MATERIALS AVAILABLE
16:55
- 17:55
CEST
LB196
POSTER
Growth hormone therapy demonstrates no significant impact on thyroid function in children with growth hormone deficiency
Agnes Linglart1; Tejasweeni Rajput2; Iris Guttmark Little3; Masanobu Kawai4; Michael Højby Rasmussen5; Tina Lund Leunbach5
MATERIALS AVAILABLE
16:55
- 17:55
CEST
LB92
POSTER
Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children born small for gestational age or with idiopathic short stature or noonan syndrome
Julie Desrochers1; Philippe Backeljauw2; Michael Højby1; Agnès Linglart3; Jun Mori4; Rory Leisegang1
MATERIALS AVAILABLE
16:55
- 17:55
CEST
LB91
POSTER
Weekly somapacitan is effective and well-tolerated in children with noonan syndrome: randomized phase 3 trial
Alexander A. L. Jorge1; Assunta Albanese2; Michael Højby3; Kamil Soltysik3; Thomas Edouard4,5; Anna Grandone6; Michael Tansey7; Jun Mori8
MATERIALS AVAILABLE
Monday, 12 May 2025
13:00
- 14:30
CEST
Symposium
Managing obesity: A lifelong perspective from childhood to adulthood
Mikael Rydén
;
Antje Körner
;
Megha Poddar
;
Morten Bøttcher
MATERIALS AVAILABLE
Tuesday, 13 May 2025
13:45
- 14:15
CEST
RC14.1 / RC14.1a
ORAL PRESENTATION
Long-term efficacy and safety of once-weekly somapacitan in children with growth hormone deficiency: 7-year results from the randomised REAL 3 trial
Lars Sävendahl1; Tadej Battelino2; Michael Højby3; Tina Leunbach3; Paul Saenger4; Lawrence Silverman5; Reiko Horikawa6
MATERIALS AVAILABLE
Keywords